Program
Carbamazepine
Also written as “carbamazepine”, “Mirdametinib and Carbamazepine” and “Radiprodil with Carbamazepine”.
Its studies are mostly in Epilepsy · Bipolar Disorder · Tuberous Sclerosis · Neuralgia · Hepatitis C, led by 4 companies.
Drug pageCarbamazepine: every studyAll 49 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GRIN Therapeuticsits history only | 21 open or running | phase 1since Apr 11, 2025 | Apr 11, 2025 | none ahead |
| H. Lundbeckits history only | 20 open or running | phase 3since May 21, 2010 | Mar 1, 2010 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Mar 17, 2010 | Mar 17, 2010 | none ahead |
| Validus Pharmaceuticals | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
Also a collaborator on its studies: Parexel, Avance Clinical Pty, Arvinas Estrogen Receptor, Ligand Pharmaceuticals, ICON Clinical Research and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Validus Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2015First study: phase 4 study in Bipolar DisorderFirst studyNCT02623504 · 17 enrolled · United States
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
The one study Validus Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02623504Bipolar Disorder · United States | 4 | Terminated | Nov 1, 2018 | 17 |
How it is read
Names in the registry
- “Carbamazepine”, 13 entries
- “carbamazepine”, 2 entries
- “Mirdametinib and Carbamazepine”, 1 entry
- “Radiprodil with Carbamazepine”, 1 entry
- “Intravenous Carbamazepine (IV CBZ)”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 6 studies
- Bipolar Disorder, 2 studies
- Tuberous Sclerosis, 1 study
- Neuralgia, 1 study
- Hepatitis C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.